Market Overview

UPDATE: Piper Jaffray Upgrades Celgene Corporation to Overweight on Reduced Revlimid Reliance

Share:
Related CELG
Stocks That Battle Cancer Were The Best-Performing Biotechs In January
Celgene's EPS Contain 'Few Surprises,' Baird Says
2 Biotech Juggernauts That Belong In Every Growth Portfolio (Seeking Alpha)

Piper Jaffray upgraded Celgene Corporation (NASDAQ: CELG) from Neutral to Overweight and raised the price target from $86.00 to $111.00.

Piper Jaffray noted, "We are upgrading CELG to Overweight from Neutral following positive top-line data from the Apremilast Phase III psoriasis studies and new 2017 guidance that supports a 25% annual EPS growth. We expect the streak of successful clinical studies and milestones, including Apremilast (psoriatic arthritis, psoriasis), Abraxane (lung cancer approval, melanoma, pancreatic), and pomalidomide (myeloma), to translate to meaningful top-line growth, lowering CELG's reliance on Revlimid performance."

Celgene Corporation closed at $85.73 on Monday.

Latest Ratings for CELG

DateFirmActionFromTo
Jan 2015CitigroupMaintainsBuy
Jan 2015Deutsche BankMaintainsBuy
Jan 2015JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (CELG)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional